InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Halstead Michael, Vice-Président Exécutif. Director active across 1 company, notably Intra-Cellular Therapies, Inc.. Cumulatively, 19 filings have been published. Split: 0 buy · 1 sell. Total volume traded: €784k. Activity tracked since 21 December 2021. The latest transaction was disclosed on 2 April 2025 (Disposition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Halstead Michael
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations19 total
21,307 shares@ US$132.0043.1% of flowCommon StockSEC:0000950170-25-049646:0
13,133 sharesCommon StockSEC:0000950170-25-036591:0
12,239 sharesCommon StockSEC:0000950170-25-032586:0
11,017 shares0Common StockSEC:0000950170-25-013763:0
22,869 shares@ US$23.948.6% of flowCommon StockSEC:0000950170-24-127275:0
12,912 shares@ US$66.1413.1% of flowCommon StockSEC:0000950170-24-029581:0
13,132 sharesCommon StockSEC:0000950170-24-028820:0
7,907 sharesCommon StockSEC:0000950170-24-021575:0
11,860 shares0Common StockSEC:0000950170-24-011400:0
46,115 shares@ US$12.738.9% of flowCommon StockSEC:0000950170-24-004320:0
15,164 shares@ US$15.473.7% of flowCommon StockSEC:0001209191-23-055207:0
16,708 shares0Common StockSEC:0001209191-23-018285:0
7,906 sharesCommon StockSEC:0001209191-23-013437:0
11,139 sharesCommon StockSEC:0001209191-23-011997:0
50,000 shares@ US$15.4712.4% of flowCommon StockSEC:0001209191-22-059507:0
7,906 sharesCommon StockSEC:0001209191-22-013356:0
11,139 sharesCommon StockSEC:0001209191-22-012392:0
19,639 sharesCommon StockSEC:0001209191-22-002989:0
25,000 shares@ US$13.8650.0% of flowCommon StockSEC:0001209191-21-071176:0
19 of 19 declarations
About Halstead Michael
Michael Halstead is Executive Vice President and General Counsel at Intra-Cellular Therapies, Inc. He is responsible for the company's legal affairs and compliance. His role is essential in navigating the complex regulatory landscape of the biopharmaceutical sector.
